Structure-based design of subtype-selective psychedelic analogs

Paper. Li H, Tang L, Zhang J et al.. Nature Communications, 17 Sep 2026.

Weekly Science Digest, 20 Jul 2026 to 2 Oct 2026, finding 8: Chemists are redesigning psychedelics for safety

A PNAS team took LSD's four-ring core apart into nine simpler molecules, mapped which parts drive the hallucinogenic effect, and found two candidates with lower hallucinogenic and heart risk. A Nature Communications group used cryo-EM structures to design compounds that activate 5-HT2A while blocking 5-HT2B, the receptor linked to heart valve damage.

How much weight it carries: Lab and mouse work. These molecules are years away from human testing. (Lab + mice, Drug design, Peer reviewed)

Weekly Science Digest, 19 Sep 2026 to 25 Sep 2026, finding 2: Designing the valve risk out of psychedelics

Cryo-EM structures guided compounds that activate 5-HT2A while blocking 5-HT2B.

Comparing the orthosteric pockets of the two receptors yielded a pharmacophore model and two compound series, confirmed by five further receptor-ligand structures. Selected compounds showed antidepressant-like effects in rodents.

Weekly Science Digest, 12 Sep 2026 to 18 Sep 2026, finding 1: Engineering out the 5-HT2B problem

Two cryo-EM studies built 5-HT2A agonists that actively antagonise 5-HT2B.

Comparing the binding pockets of the two receptors gave design rules — steric and conformational constraints in the side-extended and extended pockets — that were then used to make tryptamine and phenethylamine derivatives with the split profile. Selected compounds, including IHCH-2330, showed antidepressant-like effects in rodents.

Read the original

—
Node—
Statuslive
Throughput—